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ABSTRACT 
 
BACKGROUND. With expanding indications for cardiac device 
implantation, the prevalence of device-related infections is increasing. 
Patients with device infection and intracardiac vegetations represent a 
high-risk population with multiple comorbidities and significant 
mortality, regardless of the management strategy. 
OBJECTIVES. The purpose of this study was to assess the feasibility, safety 
and efficacy of a patient-tailored stepwise approach to the treatment of 
cardiac devices-related infective endocarditis (CDRIE), including 
antibiotic therapy and complete tranvenous device removal. 
METHODS.  Sixty-three consecutive patients with an established diagnosis 
of CDRIE were prospectively enrolled in the study between January 2010 
and August 2012. All patients underwent intra-cardiac echocardiogram 
before transvenous lead removal (TLR) to assess the presence, size and 
characteristics of lead-related vegetations. The treatment strategy 
consisted of a minimum period of at least two weeks of pre-operative 
specific antibiotic and anticoagulant therapy aimed to reduce the 
vegetation dimension and the infective burden of the intracardiac mass 
and surrounding tissues. Such treatment, in presence of stable 
hemodynamics, was continued until a TLR procedure was considered safe 
enough, without major risks of massive pulmonary embolism. After TLR, 
patients received prolonged antibiotic therapy and were followed for at 
least 6 months. 
RESULTS. All patients had lead-related vegetations and 29% of them had 
vegetations > 20 mm in diameter. 92% of patients received antibiotic 
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treatment before TLR, for a duration of 9,8 ± 5,4 weeks. TLR was 
attempted in all patients and was successful in the removal of all 
hardware in 97% of patients. Peri-procedural minor complications were 
observed in 10% of the patients; no major complication was observed. 30-
days in-hospital mortality was 3%, due to overwhelming sepsis despite 
successful complete device removal. At a follow-up time of 19,4 ± 9,7 
months, overall mortality was 10% (all deaths apart from in-hospital 
deaths were unrelated to CDRIE and its management). A composite end-
point including peri-procedural complications and follow-up events was 
used to identify predictors of Outcome Events: the only independent 
predictor resulted the presence of a defibrillator lead. 
CONCLUSIONS. Our experience suggests that treating patients with 
medical therapy (specific antibiotics and anticoagulants) also before TLR, 
even for prolonged periods, in a patient-tailored way, is a both feasible, 
safe and effective strategy to deal with CDRIE, possibly helping in 
reducing short-to-mid term mortality after device extraction, in patients 
with intracardiac lead-related vegetations. 
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BACKGROUND 
 
Infection of cardiovascular implantable electronic devices (CIED), 
including permanent pacemakers (PM) and implantable cardioverter 
defibrillators (ICD), is a severe disease associated with high mortality [1].  
Reported mortality rates of CIED–related endocarditis range from 31% to 
66% if the infected device is not removed, and 18% or less with a 
combined approach consisting of complete device removal and 
antimicrobial therapy [2,3].  
The rising number of patients with a CIED explains the increasing 
frequency of infective endocarditis (IE) in these patients. The reported 
incidence of CIED infection varies widely among studies [4]. A recent 
population-based study found an incidence of CIED infection of 1.9 per 
1000 device-years and a higher probability of infection after ICD as 
compared with PM [5]. 
Both diagnosis and therapeutic strategy are particularly difficult in these 
patients. 
A distinction should be made between local device infection (LDI) and 
cardiac device-related IE (CDRIE). 
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LDI is defined as an infection limited to the pocket of the CIED and is 
clinically suspected in the presence of local signs of inflammation at the 
generator pocket, including erythema, warmth, fluctuance, wound 
dehiscence, erosion, tenderness, or purulent drainage [6]. 
CDRIE is defined as an infection extending to the electrode leads, cardiac 
valve leaflets, or endocardial surface [7]. 
However, differentiating LDI and CDRIE is frequently difficult. In one 
study, culture of intravascular lead segments was positive in 72% of 50 
patients with manifestations strictly limited to the implantation site [8]. 
However, the possibility of intra-operative contamination of the lead tip 
cannot be excluded in these patients 
The main mechanism of CDRIE is contamination by local bacteriological 
flora at the time of device implantation. Then, the infection can spread 
along the electrode to the endocardium and the electrode tip. The 
consequence may be formation of vegetations, which can be found 
anywhere from the subclavian vein to the superior vena cava, on the 
electrode lead, on the tricuspid valve, but also on the mural endocardium 
of the right atrium and right ventricle. 
Septic pulmonary embolism is a very frequent complication of CDRIE. 
Other possible mechanisms of CDRIE include haematogenous seeding 
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from a distant focus of infection. Several factors have been associated with 
CIED infections, including fever within 24 h before implantation, use of 
temporary pacing before implantation, and early reimplantation [7]. 
CDRIE is one of the most difficult forms of IE to diagnose. Clinical 
presentation is frequently misleading, with predominant respiratory or 
rheumatologic symptoms, as well as local signs of infection [9]. 
CDRIE must be suspected in the presence of unexplained fever in a patient 
with a CIED. Fever is frequently blunted, particularly in elderly patients. 
As in other forms of IE, echocardiography and blood cultures are the 
cornerstone of diagnosis [7]. 
Echocardiography plays a key role in CDRIE and is helpful for the 
diagnosis of both lead vegetation and tricuspid involvement, 
quantification of tricuspid regurgitation, sizing of vegetations, and follow-
up after lead extraction.  
Although trans-esophageal echocardiography (TEE) has superior 
sensitivity and specificity to trans-thoracic echocardiography (TTE), and is 
cost-effective, it is recommended to perform both in suspected CDRIE 
[7,10,11].  
The generalization of multiplane technology for TEE has significantly 
improved exploration quality [12]. In addition, few other imaging 
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techniques are available, given that MRI is contraindicated in pacemaker 
carriers and CT has not been evaluated. 
If TEE remains negative and there is still suspicion, it should be repeated 
within 1 week. A repeatedly negative study should virtually exclude the 
diagnosis.  
However, both TTE and TEE may be falsely negative in CDRIE and a 
normal echographic examination does not rule out CDRIE [7].  
In some experiences, intra-cardiac echocardiography (ICE) resulted to be 
useful for accurate intraluminal scanning of the right cardiac chambers 
and great venous vessels, increasing echocardiographic sensibility and 
specificity [13,14]. 
Regardless of the technique used, the echocardiographic finding 
considered to be a major criteria in the diagnosis of CDRIE is the 
documentation of a mobile, echodense mass attached to the valvular or to 
the mural endocardium/vessel wall or to the implanted leads [7].  
However, it is usually very difficult to distinguish between a thrombus 
and an infected vegetation: recognizing that 5% of adherent masses were 
deemed thrombus in a retrospective survey [15], there will be some 
patients who are labeled as manifesting CDRIE, who may not have a lead 
infection. Masses that are detected in patients without positive blood 
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cultures or other suggestive features for infection are likely to represent 
thrombus and by themselves do not require lead removal or antibiotic 
treatment. In addition, the failure to visualize a mass adherent to a lead 
with TEE does not exclude lead infection. 
Moreover, as a rule, if huge vegetations do not generally constitute a 
diagnostic difficulty, it is often not easy to discriminate between infectious 
lesions, thrombosis, fibrin deposits or pannus, in case of detection of 
microfilaments, sheath-like structures along the leads, strands and other 
uncommon structures whose nature is still unknown and significance is a 
matter of debate. 
Additionally, echocardiography is important in assessing the maximum 
vegetation size prior to intervention, as many vegetations may embolize 
and break up into the lung circulation during transvenous lead removal 
(TLR). 
Blood cultures are positive in 77% of cases of CDRIE [16]. Staphylococci 
are the most frequent pathogens, S. aureus being predominant in the acute 
forms of CIED infection [17].  
Blood cultures can be positive with and without lead or valve vegetations 
or can be negative despite intracardiac vegetations.  
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The Duke criteria are difficult to apply in these patients because of lower 
sensitivity. Modifications of Duke criteria have been proposed, to include 
local signs of infection and pulmonary embolism as major criteria [9]. 
Finally, lung CT and lung scintigraphy are considered both useful to 
detect pulmonary septic embolism. 
In the majority of patients, CDRIE must be treated by prolonged antibiotic 
therapy associated with device removal [2,7]. 
In the case of definite CDRIE, medical therapy alone, in fact, has been 
associated with high mortality and risk of recurrence. For this reason, 
CIED removal is recommended in all cases of proven CDRIE and should 
also be considered when CRDIE is only suspected, in the case of positive 
cultures obtained in different days (persistent bacteremia), when there is 
no clear source of the positive cultures in the heart, on the leads, or from 
other parts of the body (occult infection) [2,7]. 
CIED extraction can be performed percutaneously without need for 
surgical intervention in the majority of patients. 
As newer technologies have emerged and the experience has grown, TLR 
has become the preferred method for removal of CIED hardware. 
However, these procedures involve significant risks, including cardiac 
tamponade, hemothorax, pulmonary embolism, lead migration, and 
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death, even in experienced hands. Thus, the performance of these 
procedures should be limited to centers with the appropriate facilities and 
training, which includes the presence and imminent availability of 
cardiothoracic surgery on site, to provide backup in the event of 
complications. In high-volume centers, TLR can be accomplished 
relatively safely with a high rate of success.  
A primary surgical approach to lead removal in patients with CIED 
infection should be limited to patients who have significant retained 
hardware after attempts at percutaneous removal.  
Another scenario in which a preference for surgical lead removal has been 
advocated is in patients with lead vegetations > 2 cm in diameter, because 
of concerns about the risk of pulmonary embolism with TLR, as a result of 
vegetation displacement during extraction, as it frequently occurs, 
particularly when vegetations are large [18].  
Experience suggests, however, that percutaneous removal in patients with 
large vegetations can be done without precipitating a clinically apparent 
pulmonary embolism. These episodes, in fact, are frequently 
asymptomatic, and percutaneous extraction remains recommended even 
in cases of large vegetations, since overall risks are even higher with 
surgical extraction [2,7]. 
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Some authors recommend surgery to be performed in patients with very 
large vegetations [16,19], when percutaneous extraction is technically 
impossible, or when severe tricuspid valve IE is associated.  
When performed, surgery requires good exposure under extracorporeal 
circulation to allow complete removal of all foreign material. Excision of 
all infected contact lesions at the level of the tricuspid valve, right atrium, 
right ventricular free wall, and distal superior vena cava is essential. 
However, mortality associated with surgical removal is high in these 
frequently elderly patients with associated co-morbidities [20]. 
With regard to vegetation size, the optimal approach is a matter of debate. 
Surgical extraction may be preferred for patients with larger vegetations; 
however, mortality rates up to 12.5% have been reported after surgical 
lead extraction [7].  
It is thought that vegetations with a high probability of obstructing a main 
stem of the pulmonary artery (a vegetation >2 cm in diameter might be of 
borderline size) should be removed by open heart surgery.  
However, several patients with vegetations >2 cm are described to have 
undergone successful TLR, especially patients with high perioperative risk 
and prior complex cardiac operations, often without major adverse events 
such as severe pulmonary embolism [21,22]. 
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Moreover, a risk factor analysis [23] was conducted that examined clinical 
and echocardiographic variables that identified patients with CIED 
infections who were at increased risk of mortality: size and mobility of 
lead vegetations were not independently associated with mortality. 
However, vegetation size, shape, and friability, presence of a patent 
foramen ovale, atrial or ventricular septal defect and other surgical 
indications and goals all need to be considered when making this decision.  
The largest vegetation size, in presence of which a TLR procedure can be 
safely performed, remains to be defined.  
Decisions regarding percutaneous versus surgical removal of leads with 
vegetations larger than 2 cm in diameter should be individualized and 
based on patient’s clinical parameters and the extractor’s evaluation [22]. 
Antimicrobial therapy is adjunctive in patients with CIED infection, and 
complete device removal should not be delayed, regardless of timing of 
initiation of antimicrobial therapy. It should be individualized and the 
selection of the appropriate antimicrobial agent should be based on 
culture and susceptibility results if possible. 
There are no clinical trial data to define the optimal duration of 
antimicrobial therapy for CIED infections, regardless of the extent of 
infection, or to determine when conversion to an oral agent is appropriate 
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once complete device removal has been achieved. Factors that influence 
medical decision making include the extent of device infection, the 
causative organism, the presence and duration of bloodstream infection, 
and associated complications such as valvular involvement, septic 
thrombophlebitis, or osteomyelitis.  
Blood cultures should be obtained from all patients after device removal. 
When CIED infection is limited to the pocket site, 7 to 10 days of therapy 
after device removal is reasonable if the presentation is device erosion 
without inflammatory changes; otherwise, 10 to 14 days of antimicrobial 
treatment is recommended.  
Therapy can be switched to an oral regimen once susceptibility results are 
known if there is an oral agent available that is active against the pathogen 
and the infected CIED has been removed. 
At least 2 weeks of parenteral therapy is recommended after extraction of 
an infected device for patients with bloodstream infection.  
Patients with sustained (>24 hours) positive blood cultures despite CIED 
removal and appropriate antimicrobial therapy should receive parenteral 
therapy for at least 4 weeks, even if TEE is negative for valvular 
vegetations. 
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It is intuitive that adequate debridement and control of infection at all 
sites, both at the generator site and metastatic, if present, sould be 
achieved before new device placement. The contralateral side is preferred 
for new device placement, if required. 
It is Class I recommendation (Level of Evidence: C) a duration of 
antimicrobial therapy of at least 4 to 6 weeks for complicated infection (ie, 
endocarditis, septic thrombophlebitis, or osteomyelitis) or if bloodstream 
infection persists despite device removal and appropriate initial 
antimicrobial therapy [22]. 
It is imperative to make an assessment of the need for new device 
placement in each patient who needs to undergo the removal of an 
infected CIED.  
One third to one half of patients in some series will not require new CIED 
placement. There are several factors, including reversal of the pathological 
processes that precipitated the need for CIED implantation, changing 
clinical circumstances, and lack of appropriate clinical indication initially, 
that obviate the need for new CIED placement and thus result in 
avoidance of new device infection. 
On the other hand, removal of infected hardware should not be attempted 
until a careful assessment of a new implantation strategy has been 
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performed, particularly in patients with pacemakers for complete heart 
block and resynchronization therapy devices. When implantation of a new 
device is necessary, it should be performed on the contralateral side if 
possible to avoid relapsing device infection. If this is not possible, a 
transvenous lead can be tunneled to a device placed subcutaneously in the 
abdomen.  
Implantation is usually postponed to allow for resolution of infection, but 
patients who are PM dependent represent a challenge, because they 
cannot be discharged home with a temporary pacemaker.  
There have been no prospective trial data that examined timing of new 
device implantation and risk of relapsing infection; however, several 
investigators recommend waiting for blood cultures to be negative before 
a new device is placed [22]. 
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STUDY 
 
Objectives 
The treatment of patients with established diagnosis of CDRIE includes 
removal of all CIED hardware and a prolonged course of antimicrobial 
therapy.  
Percutaneous extraction of infected devices presenting with large lead 
vegetations is associated with a variable risk of periprocedural pulmonary 
embolism and therefore, in cases of vegetation size of 2 cm in diameter or 
greater, an open surgical removal is usually to be considered [7, 22].  
At our Institution, a multidisciplinary approach involving cardiac 
electrophysiologists experienced in TLR, infectious disease consultants 
and cardiac surgeons produced an original way of treating patients with 
CDRIE and large vegetations, that aims to start a medical treatment based 
on antibiotic and anticoagulant therapy before TLR, to continue it for a 
variable duration without keeping the patient hospitalized and to perform 
lead extraction percutaneously once vegetation size has decreased enough 
to avoid the risk of serious massive pulmonary embolism and once the 
bacterial burden of infected tissues has been significantly reduced. After 
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TLR, patients receive a course of antimicrobial treatment as recommended 
by the current guidelines.  
In this study we had the objective of assessing the safety and efficacy of 
this patient-tailored stepwise approach. 
 
Methods 
We prospectively enrolled in the study all consecutive patients admitted 
at our Institution (mostly referred from other Italian Hospitals) from 
January 2010 to August 2012 with an established diagnosis of CDRIE, 
according to the modified Duke criteria [7,22]. 
At first admission, a complete characterization of patient’s clinical profile 
was obtained and all patients underwent TTE and ICE to confirm the 
diagnosis. ICE was performed to assess not only a better size 
quantification and characterization of the masses, but also to get some 
useful elements to guide the TLR procedure.  
Intracardiac vegetation was defined as a discrete, echogenic, oscillating 
mass found on a valve, lead, or endocardial surface and confirmed in 
multiple views by echocardiography. 
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At least two sets of blood cultures were collected and an infectious disease 
consultant was contacted to set up an antibiotic treatment based on germ 
identification, when available.  
TLR was performed only if vegetation size was < 2 cm in diameter and if 
the patient had already received a course of appropriate antibiotic 
treatment for at least two weeks before admission at our Institution, or 
fulfilled it during hospitalization.   
The extraction procedure has been previously described [24,25]. After 
device removal, the leads were examined visually and by means of 
fluoroscopy in their intravascular segment; the proximal end was then 
clipped and a standard stylet was inserted into the lead. Lead extraction 
was attempted by means of gentle manual traction. If this proved 
unsuccessful, operators crossed to mechanical dilatation with a single-
sheath (i.e. non-telescopic) technique. This involved inserting and 
advancing multi-sized dilators (Cook Intravascular Inc., Leechburg, PA, 
USA) through the venous entry-site, as first choice, or through the right 
internal jugular vein, if required [24,25]. A surgical debridement of the 
device pocket was performed, using electrocautery and blunt dissection. 
Procedural outcomes (i.e. success and complications) were defined 
according to previously published guidelines [2,26].   
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Patients with vegetation size of 2 cm or greater in diameter or who did not 
have already received an antibiotic treatment for at least two weeks, in 
presence of stable hemodynamics, were, instead, discharged; in fact, based 
upon the infectious disease specialist advice, it was usually selected a 
treatment that did not require patient’s hospitalization and could be orally 
administered or possibly given as an outpatient treatment.  
The recommended duration of the medical therapy, in case of persistent 
stability of hemodynamics, was variable between at least 2 and 4 weeks 
and was decided based upon each patient’s specific characteristics; in case 
of huge vegetations, it was usually added an anticoagulant therapy in 
order to reduce mass dimensions.  
Once completed the course of antibiotic and anticoagulant home 
treatment, a novel admission served to re-assess the status of the patient, 
their blood tests and cultures and vegetation size, by means of TTE and 
ICE.  
Another cycle of 4-weeks antibiotic and anticoagulant home therapy 
would have been prescribed in case of vegetation size still > 2 cm, 
otherwise the patient underwent TLR, as above described.  
In case of persistently large vegetations despite long periods of 
appropriate antibiotic and anticoagulant treatment, it was discussed the 
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indication to surgical removal, but, in our series of patients, either due to 
unacceptably high surgical risk (and lacking concomitant indications to 
surgery), or to patient refusal, a percutanous removal of the system was 
attempted also in several cases of very large vegetations. 
The vegetation size considered for the study was the larger diameter of the 
mass that was observed at an ICE made at some of the pre-operatory 
echocardiographic assessments or at the ICE performed at the time of TLR.  
ICE was performed using a 9 F / 9 MHz ultra-ICE catheter-based 
ultrasound transducer (EP Technologies, Boston Scientific, San Jose, CA, 
USA). The Ultra ICE catheter was introduced percutaneously into a 
femoral vein through a short venous introducer (Cordis, Avanti+) and 
advanced under limited fluoroscopy. 
Examination started with the ultra-ICE catheter positioned initially in the 
left or right subclavian vein, depending on the cardiac lead venous-entry 
side. Subsequently, the ultra-ICE catheter was withdrawn through the 
right atrium to the inferior vena cava in order to obtain the so-called axial 
imaging planes. Several slice sections on the axial plane were achieved by 
applying an ideal perpendicular angle of incidence of the ultrasound beam 
to the vessels and right atrium wall in the center of their cavity. Full 
interrogation included modified tomographic imaging planes at the vessel 
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(subclavian vein, innominate vein, superior vena cava), atrial, tricuspid, 
and ventricular plane. 
ICE image quality was adequate to assess all structures involved in TLR 
[13,14]. In particular, all the following structures could be detected: cardiac 
leads; areas of fibrous adherence; vegetations: they can appear as variably 
shaped hyperechogenic structures, differently adherent to catheter or 
cardiac structures even if located at atypical intravascular locations (such 
as the venous tree); vein permeability: essential to detect total or partial 
obstruction and to check permeability of other veins (also in order to plan 
subsequent lead reimplantation). 
Additionally, intraprocedural imaging with ICE was important for 
complication monitoring, complementary to fluoroscopy. 
Following the extraction procedure, the patients received a prolonged 
course of antibiotic treatment, based on published guidelines [7,22]. 
Reimplantation was performed at the discretion of the treating physician. 
The strategies were different according to whether or not the patient was 
PM dependent. In the first case, if the patient was apyretic and the 
preoperative cultures were negative, an early reimplantation usually after 
72 hours was performed; in the second, the new device was implanted in 
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the contralateral site after usually 1 week of post-extraction antibiotic 
therapy.  
Patients were followed for at least 6 months from the date of TLR, by 
means of visits and/or phone calls. 
Statistical analysis 
Continuous variables were expressed as mean ± 1 standard deviation or 
median (range) when appropriate and categorical variables as 
percentages. Groups were compared for categorical data using Fisher’s 
exact test and for continuous variables using analysis of variance followed 
by Fisher’s protected least significant difference for multiple comparisons. 
All tests were 2-sided; a P<0.05 was considered to be significant. For non 
parametric variables, appropriate non-parametric tests (i.e. the Kruskall 
Wallis test and the Spearman correlation) were used. The predictors of 
peri-procedural adverse events were assessed at Logistic regression 
analysis. Only variables with a P<0.05 at univariate logistic analysis were 
entered in the multivariate model. Kaplan-Meier statistics followed by 
Log-Rank test was used to evaluate the predictors of adverse events. 
Statistical analyses were performed using JMP statistical software (SAS 
Institute Inc, version 4.0.0) and Stata software (Stata Statistical Software: 
Release 10, StataCorp. 2007, College Station, TX). 
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Results 
A total of 63 patients were prospectively enrolled in the study. The patient 
demographics are summarized in Table 1. 
Table 1 
Number of patients 63 
Sex: male 49 (78) 
Age (years) 65 ± 16 
Comorbidities 
Congestive heart failure 32 (51) 
Diabetes 18 (29) 
Chronic kidney disease 17 (27) 
Coronary artery disease 10 (16) 
Previous cardiac surgery 7 (11) 
Valvular prosthesis 4 (6) 
Chronic obstructive pulmonary disease 7 (11) 
Type of device 
Pacemaker 23 (36) 
Implantable cardioverter defibrillator 19 (30) 
Biventricular pacemaker 1 (2) 
Biventricular defibrillator 20 (32) 
Left ventricular ejection fraction 47 ± 13 
Device implantation indication* 
Atrio-ventricular block 14 (22) 
Sinus node dysfunction 10 (16) 
Primary prevention of sudden cardiac death 25 (40) 
Secondary prevention of sudden cardiac death 14 (22) 
Resynchronization therapy 20 (32) 
Number of leads/patient 
Total 2 (1-4) 
Targeted for extraction 2 (1-4) 
Age of the oldest lead targeted for extraction (months) 96 ± 66 
Months from most recent device-related procedure 26 ± 22 
Data are expressed as “number (percentage)”; “mean ± standard deviation” or 
“median (range)”. 
*The sum does not match with number of patients, due to multiple indication in 
some cases. 
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Data about the characteristics of CIED infection, its timing and medical 
treatment are summarized in Table 2. 
Table 2 
Infection history and characterization 
Time from first device infection diagnosis to extraction (months) 11,3 ± 20,3 
History of fever 59 (94) 
Lead vegetation detected at echocardiograms 63 (100) 
Concomitant infection of device pocket  38 (60) 
Vegetation size at intracardiac echo (mm) 14,5 ± 9,4 
Patients with vegetation size 20 mm or larger 18 (29) 
Positive peripheral blood cultures 47 (75) 
Atrial blood sampling during intracardiac echo 53 (84) 
Pre-extraction antibiotic treatment 
Patients treated  58 (92) 
Total duration of pre-extraction antibiotic therapy (weeks) 9,8 ± 5,4 
Patients treated with oral antibiotics  42 (67) 
Duration of oral therapy alone (weeks) 7,1 ± 5,5 
Patients treated with oral plus parenteral antibiotics 51 (81) 
Duration of combined (oral plus parenteral) treatment (weeks) 5,3 ± 4,1 
Post-extraction antibiotic treatment (weeks) 3,8 ± 3,5  
Data are expressed as “number (percentage)” or “mean ± standard deviation” 
 
The majority of patients (60%) showed signs of device pocket infection 
and had positive blood cultures (75%). All patients had lead vegetations; 
29% of patients had large vegetations, 20 mm in diameter or larger.  
Infection of the device was usually present from several months (11,3 ± 
20,3) and most patients (92%) had received a prolonged course (9,8 ± 5,4 
weeks) of antibiotic treatment at the time of TLR. All patients received 
post-procedural appropriate antibiotic therapy, according to guidelines, 
for a duration of 3,8 ± 3,5 weeks. 
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The results of peripheral blood cultures, early taken during the diagnostic 
work-up, are summarized in Figure 1. 
Figure 1 
 
The majority of cases of CDRIE in our patient series, as shown, were due 
to Staphylococci (n=38, 61%), of which 10 cases to S. aureus (16%), 17 cases 
(27%) to S. epidermidis and 11 cases (18%) to Coagulase-negative 
Staphylococci other than S. epidermidis. A minority of cases were due to 
other Gram-positive species (4: S. viridans, P. acnes, C. jeikeium, 
Enterococcus spp), to Gram-negative germs (4: E. cloacae, P. aeruginosa, 
H. influenzae, Borrelia spp) and one patient resulted positive to C. 
albicans. Blood cultures tested negative in 16 cases (25%). 
28 
 
The identification of a microorganism in blood cultures resulted associated 
with a significantly longer period of antibiotic treatment before extraction, 
as shown in Figure 2. 
Figure 2 
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Moreover, the identification of a microorganism in blood cultures resulted 
associated with a significantly smaller dimension of the vegetation 
detected at ICE, as shown in Figure 3.  
Figure 3 
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TLR was attempted in all patients and was successful in removal of all 
hardware in the great majority of cases (n=61, 97%): the procedure was 
unsuccessful only in two cases. In one case the technique was not effective 
and the patient underwent surgical extraction of two pacing leads (148 
months old), with concomitant implantation of two epicardial leads, 
without complications. In another case, a lead fragment was abandoned 
(the patient was carrier of a dual chamber ICD and had three leads, of 
which only two were completely extracted), and this did not bring 
complications. The patient underwent a subcutaneous ICD system 
implantation two weeks later and did not report adverse events in the 
follow-up.  
Radiological success was not achieved also in another case, in which only 
the fractured atrial lead tip was abandoned in the auricle, without 
sequelae: in this case, however, the extraction procedure was considered 
clinically successful.  
Minor peri-procedural complications occurred in 6 patients (10%) and are 
summarized in Table 3: two patients had symptomatic embolization of 
part of the vegetation into lung circulation, that was promptly resolved 
and passed without apparent consequences; two patients had hematomas 
at the pocket site, one of which requiring blood transfusion; in two cases 
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there was a minor pneumothorax that was resolved by means of thoracic 
drainage.  
All patients entered the follow-up, but 61 (97%) were followed for at least 
six months (follow-up duration 19,4 ± 9,7 months), by means of visits 
and/or phone calls (2 patients were lost to follow-up). The events recorded 
in the follow-up are summarized in Table 3.  
Table 3 
Peri-procedural complications 6 (10) 
Symptomatic pulmonary embolism 2 (3) 
Pocket site hematoma 2 (3) 
Need for blood transfusion 1 (2) 
Minor pneumothorax 2 (3) 
Events at follow-up 8 (13) 
Death 6 (10) 
Sepsis (in hospital death, < 1 month from extraction) 2 (3) 
Prolonged diarrhea (32 months after extraction) 1 (2) 
Dementia (23 months after extraction) 1 (2) 
End stage renal failure (7 months after extraction) 1 (2) 
Acute pancreatitis (19 months after extraction) 1 (2) 
Dislodged lead repositioning (1 month after reimplant) 1 (2) 
Decubitus of an abandoned epicardial lead 1 (2) 
Data are expressed as “number (percentage)” 
 
Only the two septic deaths occurred during hospitalization within one 
month from successful extraction, appear to be strictly related to the 
clinical problem of CDRIE.  
Given the small number of events in the follow-up and the small amount 
of procedural complications observed, all these events were considered 
together in the statistics, to formulate a composite end-point, named 
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Outcome Events. Many clinical variables were tested as predictors of 
Outcome Events, as indicated in Table 4, that summarizes the results of 
the univariate and multivariate analysis performed.  
Table 4 
Variables 
Univariate            
OR (95% CI) 
P  
Multivariate        
OR (95% CI) 
P  
Age 0.99 (0.96 – 1.03) 0.728 NA NA 
Male sex 0.51 (0.15 – 1.75) 0.287 NA NA 
Diabetes 0.61 (0.17 – 2.20) 0.452 NA NA 
Chronic kidney disease 1.98 (0.62 – 6.38) 0.251 NA NA 
Congestive heart failure 3.42 (1.04 – 11.26) 0.043 NS NS 
Coronary artery disease 0.67 (0.20 – 2.24) 0.965 NA NA 
Left ventricular ejection fraction 0.96 (0.92 – 1.00) 0.062 NA NA 
Pocket infection 1.19 (0.39 – 3.59) 0.762 NA NA 
Vegetation size 0.98 (0.92 – 1.05) 0.612 NA NA 
Vegetation size 20 mm or greater 0.62 (0.17 – 2.24) 0.460 NA NA 
Presence of ICD Lead 3.75 (1.07 – 13.11) 0.038 4.67 (1.15 – 19.01) 0.032 
Lead number >2 3.31 (1.08 – 10.17) 0.036 NS NS 
Pacemaker dependency 1.25 (0.32 – 4.83) 0.746 NA NA 
Time from last device-related 
intervention 
0.96 (0.93 – 1.00) 0.057 NA NA 
Time from infection diagnosis to 
extraction 
1.00 (0.97 – 1.03) 0.870 NA NA 
Age of the oldest extracted lead  0.99 (0.98 – 1.00) 0.130 NA NA 
Positive blood cultures 2.83 (0.56 – 14.27) 0.210 NA NA 
Total duration of antibiotic treatment 1.08 (0.97 – 1.19) 0.150 NA NA 
OR: Odds Ratio; CI: Confidence Interval; NA: not available; NS: not significant; ICD: implantable 
cardioverter defibrillator 
 
At univariate analysis, three variables resulted significant predictors of 
Outcome Events: an history of congestive heart failure, the presence of an 
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ICD lead and having a number of leads > 2. At multivariate analysis, only 
the presence of an ICD lead resulted as an independent predictor of 
Outcome Events. 
Kaplan-Meier statistics to evaluate the predictors of Outcome Events 
showed significant results in differentiating event-free survival curves, 
with the grouping variables of presence of an ICD lead (Figure 4) and 
number of leads > 2 (Figure 5). 
Figure 4 
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White dots: patients with ICD leads; black dots: pacemaker patients. Time is expressed in months. 
 
Figure 5 
 
 
 
 
 
 
 
 
 
White dots: patients with more than 2 leads; black dots: patients with 2 or less leads.  
Time is expressed in months. 
Logrank test  
P= 0.0195 
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The majority of patients underwent CIED reimplantation during the same 
hospitalization as TLR (n=36, 57%) and the procedure was performed after 
5,2 ± 4,4 days from TLR, with a duration of hospital stay of 13,9 ± 8,2 days. 
Eight patients (12%) were discharged without performing reimplantation 
during the same hospitalization, for various reasons: apart from cases in 
which there was lack of ongoing indication or patient’s refusal, in some 
cases with very large vegetations without PM dependency or in primary 
prevention ICD carriers, the patient was discharged and an ICE evaluation 
was planned after at least 1 month of antibiotic and anticoagulant therapy 
to demonstrate reduced vegetation dimensions and eventually proceed to 
reimplantation.  
In some cases, the persistence of the mass inside the right chamber, in fact, 
is not necessarily associated with continued illness, as confirmed by 
resolution of fever, normal white blood cell count and labeled leukocyte 
imaging that is repeatedly negative for infection. In such cases, 
reimplantation is still considered safe. 
Seven patients (11%) received a wearable defibrillator at discharge and six 
of them received a new ICD implantation after 112 ± 51 days.  
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Discussion 
Cardiac device infection is a serious, emerging disease with a 210% 
increase in incidence between 1993 and 2008. In-hospital charges for this 
complication are estimated to be at least US $146000 per case in the United 
States. CDRIE in particular has a substantially higher mortality rate than 
cardiac device infection without endocarditis [27]. 
Data from randomized, controlled trials to guide the management of CIED 
infections are lacking.  
Recommendations for complete extraction of the device, the route of 
administration and the duration of antimicrobial therapy, and the timing 
for placement of a new device are largely based on observational data, 
clinical experience, or both.  
Observations from several medical centers universally support complete 
removal of the device to cure infection and reduce morbidity and 
mortality [28, 29]. 
A variety of percutaneous lead-removal techniques are available, and only 
a small minority of patients require open cardiovascular surgery for 
complete device removal.  
The choice of percutaneous or open surgical removal should take into 
account not only the size of a vegetation, as visualized on 
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echocardiography, but also several other factors, including the patient’s 
age, how long the device has been in place, the type of device, the number 
of retained leads from previous devices, the presence or absence of a 
history of difficult or complicated percutaneous extractions, and the 
patient’s status with respect to coexisting conditions.  
Complications, including death, may occur with either percutaneous or 
surgical removal of the device. 
Major complications are reported in less than 2% of patients who undergo 
percutaneous removal [2], but the rate may be much more high with 
surgical removal, which is generally performed after unsuccessful or 
complicated percutaneous extraction.  
In a recently published study about a large prospective cohort of patients 
with CDRIE [27], in-hospital and 1-year mortality rates were 14.7% and 
23.2% respectively and it was observed a survival benefit at 1 year for 
device removal during the initial hospitalization (19.9% of patients, who 
underwent device removal during the index hospitalization had died at 1 
year, versus 38.2% who did not undergo device removal). 
In a retrospective survey, patients with CIED infections were divided into 
two groups of systemic or local infection: in the first group, the in-hospital 
mortality was 29% (5% in the second group) despite complete CIED 
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removal. It was found that early TLR was associated with better in-
hospital survival and shorter hospital stays and this association was 
statistically significant in the population as a whole (TLR performed 
within 3 hospitalization days was associated with lower in-hospital 
mortality), with a statistical trend in the higher risk subgroup with 
endovascular infection or endocarditis [30]. 
In a retrospective study about TLR in 100 patients with intracardiac 
vegetations detected by TEE (mean diameter 16 mm), there was a 5% rate 
of only minor complications, post-operative 30-day mortality was 10% and 
no death was directly related with the extraction procedure (multiple 
comorbidities and overwhelming sepsis were considered responsible of 
the natural progression, despite TLR, of the disease that finally caused the 
observed short-term deaths) [31]. 
In a more recent study [32], 129 patients with lead-associated vegetations 
were analyzed: 13,2 % of patients underwent surgical removal; 10,9 % was 
the overall in-hospital mortality and 6,2 % was the overall rate of major 
complications, regardless of the modality of device removal. The Authors 
found that the clinical presentation of CDRIE was influenced by the size of 
the lead vegetation (they used 1 cm as the cut-off value for separating 
patients in two groups). Complications of lead removal were more 
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common in those with larger vegetations, driven by complications in those 
requiring an open surgical approach.  
A study by Golzio PG and Coll. [33] showed that prevalence of 
intracardiac lead vegetations in patients treated with lead extraction was 
40%, when transesophageal echocardiography was extensively performed 
in all patients with infective indications. Vegetations were, as expected, 
mainly observed in sepsis/systemic infection, but, more interestingly, they 
were also found in local infections and chronic draining sinus 
(approximately in one-third of the cases), where they represented an 
‘unexpected’ finding according to traditional knowledge. The Authors 
showed how vegetation occurrence play a key role in stratifying the risk of 
the extraction procedure and in driving further therapeutic decisions and 
concluded that vegetations should be accurately investigated before 
extraction in any case showing infective indications, as well as in patients 
with only local signs or symptoms. It was confirmed the importance of 
factors previously associated with infections, according to literature data: 
replacement, revision, previous reparative procedures, renal failure, 
dialysis, CRT devices, absence of antibiotic prophylaxis, and long-
standing infection were associated with vegetations; increased WBC count 
and dialysis resulted independent risk factors for vegetations. The study 
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was also probably the only one in which the therapeutic approach 
considered an antibiotic treatment before TLR in patients with large 
vegetations: the Authors stated that their better outcomes (1,5% in-
hospital death) could be related to the use of a longer antibiotic course 
before TLR. 
However, the generally observed high rates of mortality of CDRIE 
emphasize the need for improved preventive measures, including optimal 
skin decontamination and appropriate antibiotic administration at the 
time of cardiac device insertion or manipulation, as well as careful 
attention to any invasive or intravascular procedures performed after 
device implantation. 
Our experience in dealing with CDRIE as a tertiary referral center with 
recognized expertise in TLR suggested us that, particularly when a patient 
shows large vegetations and does not present hemodynamic instability, it 
is possible and safe to delay the procedure of TLR, allowing the patient to 
receive some weeks of appropriate and specific antibiotic and 
anticoagulant therapy, while waiting for the complete device removal and 
the subsequent unanimously recommended prolonged specific antibiotic 
treatment. This kind of strategy met the support of our infectious disease 
consultants. 
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Pre-extraction anticoagulation therapy has a rationale in the fact that the 
involvement of endovascular and intracardiac structures in the infectious 
process related to the CIED leads, with formation of a vegetant mass, 
needs the interaction of the microbial flora with thrombotic material: 
anticoagulation could help in the progressive fragmentation of the mass, 
at the same time allowing antibiotics to reach the bacterial colonies.  
We believe that, in presence of lead-related vegetations, especially when 
they are large, a specific antibiotic treatment together with an 
anticoagulant therapy, given to the patient before TLR, could not only 
produce a significant reduction in the size of the mass, thus reducing the 
risk of massive embolization, but also contribute to sterilize the vegetation, 
the surrounding tissue and possibly the device pocket (when signs of local 
infection are concomitant), so that, when performing TLR, the main source 
of bacteremia and therefore of bloodstream infection is possibly 
represented only by the infected hardware.  
The only concern about this treatment strategy is about very large fungal 
lead-related vegetations, because in these cases antimicrobial therapy is 
often not able to reduce the size of the mass despite long term 
administration and therefore a surgical removal is often required.  
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In this preliminary study, our approach proved to be feasible, safe and 
effective and results about in-hospital death and mid-term outcome are 
very encouraging, if compared with the above-mentioned data about 
similar populations published in the literature.  
The observed complication rate was low and they all were minor 
complications.  
In-hospital mortality was 3% and none of the deaths occurred in the 
follow-up was related to the problem of CDRIE and its management, 
being instead expression of serious comorbidities. 
Our population consisted of very ill patients, considering that 62% of them 
were carriers of an ICD, 51% suffered from congestive heart failure and 
34% had a biventricular device. Moreover, the average dwelling time of 
the leads that were targeted for extraction was 96 ± 66 months, accounting 
for a possibly high average difficulty of TLR procedures.  
In this patient series, as well as in our previous experience, the presence of 
large vegetations, even bigger than 30 mm in diameter, in patients treated 
for a long time with antibiotics and anticoagulants, did not prevent the 
possibility of a safe percutaneous extraction, without clinical compromise 
despite a likely underestimated rate of silent lung embolization, and acute 
and long term outcome were very good.  
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In our hypothesis, needing confirmation by further studies, our low rate 
(3%) of in-hospital mortality for post-extraction overwhelming sepsis 
could be related to a kind of sterilization of the vegetant mass, the 
surrounding venous and heart structures and the device pocket, that is 
gained by means of preliminary antibiotic treatment, combined with 
subsequent device removal and continuing antimicrobial therapy.  
In this kind of patients, in fact, the vegetations sometimes disappear with 
extraction, but the remaining right-sided infected heart and lung 
environment is unknown and the mortality from uncontrolled sepsis, with 
and without heart failure, despite device removal and subsequent 
appropriate antibiotics, could, in part, be due to residual infected 
inflammatory tissue, possibly within the right heart, lung, or implant 
pocket [34].  
So, the rationale of treating patients with prolonged courses of antibiotics 
before TLR is also the need to control the infection at the site of this 
supposed infected inflammatory tissue and possibly to make it sterile 
when a TLR is performed, thus reducing the risk of bacterial seeding and 
bloodstream infection after TLR.  
It is important to underline that the long term pre-operative antibiotic 
treatment (92% of our patients received 9,8 ± 5,4 weeks of antibiotic 
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therapy before TLR) is generally given as an outpatient or home therapy, 
thus reducing hospitalization duration and its overall costs.  
Time from first device infection diagnosis to TLR is particularly high in 
our series of patients also because many of them were referred to our 
Institution after prolonged periods of conservative treatment attempts, 
either with antibiotics alone or with antibiotics plus device pocket surgical 
revisions. Our strategy should be evaluated in this setting. Although too 
much time has been wasted before referring a patient in a center 
experienced in the CDRIE management, in our opinion it would be 
advisable not to abandon the opportunity to best treat the lead infection 
with a proper duration of the specific antibiotic treatment.  
Our results underline the importance of identifying the pathogens from 
blood cultures, possibly before the start of antibiotic therapy: the 
identification of germs was, in fact, associated with significantly smaller 
vegetation sizes and longer duration of antibiotic treatment before TLR 
and this could mean that a culture-based specific therapy given to a 
patient for prolonged duration could help in reducing vegetation 
dimensions.   
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Moreover, it is worth emphasizing that no death occurred in patients in 
whom, because of a huge vegetation, TLR procedure was delayed, thus 
increasing the duration of the preoperative antibiotic treatment. 
Microbiology in our patient population is consistent with data reported in 
the literature, both in the percentage of positive early taken blood cultures, 
and in the species of involved microorganisms, with predominance of 
Staphylococci [17,22].  
Given the small number of events in the follow-up and the small amount 
of procedural complications observed, all these events were considered 
together in the statistics, to formulate a composite end-point, named 
Outcome Events: limitations in the correct interpretation of statistics in 
presence of composite end-points are well known. We only point out that 
the observed significant predictors of Outcome Events probably identify a 
kind of sicker patient (congestive heart failure, ICD patients, biventricular 
device patients), that is likely to have more comorbidities, to be older and 
frailer.    
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Study limitations 
In this patient series, we have only data concerning the maximum 
measured dimensions of the vegetations, during the entire course of 
clinical observation, from early CIED infection diagnosis to TLR.  
It would be of crucial importance, for a better characterization of the 
impact of treatment on the pre- and post-operative features of the 
vegetation, to have echocardiographic data about each step of treatment, 
in order to assess the extent of the effective reduction in vegetation size 
after antibiotic and anticoagulant therapy prior to extraction and to 
monitor the subsequent evolution of the intracardiac mass after TLR.  
Our echocardiographic data were all obtained at ICE: the possibility of 
making comparisons between various echocardiographic methods (TTE, 
TEE, ICE) in assessing vegetation dimension and features would add 
important details, possibly very useful for the diagnostic management of 
this kind of patients. 
The lack of a control group of matched patients treated with a different 
approach does not permit comparisons. Only comparing the results of our 
strategy with those achieved by other groups applying different 
approaches in similar populations are possible at the moment.  
45 
 
The proposed tailored stepwise approach of management implies that 
given therapies are not fully standardized among all patients, mainly in 
time duration (for example, duration of pre-operative treatment was 
critically dependent on each patient’s specific characteristics), although 
they are uniformly designed. 
Our study was conducted at a single tertiary referral center with 
experience in TLR, and its results and conclusions may not apply to 
different Institutions.  
    
Conclusions 
As indications for device implantation expand, the prevalence of device-
related infections will increase.  
Vigilant recognition and appropriate management with both antibiotics 
and complete device removal should be the cornerstones of therapy.  
Patients with CIED infection and intracardiac vegetations represent a 
high-risk population with multiple comorbidities and significant 
mortality, regardless of management strategy.  
Our experience suggests that treating patients with medical therapy 
(specific antibiotics and anticoagulants) also before TLR, even for 
prolonged periods, in a patient-tailored way, is both feasible and safe and 
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possibly helps in reducing short-to-mid term mortality after device 
extraction, in patients with intracardiac lead-related vegetations. 
Further studies are needed to strongly assess the best ways to treat 
patients with CDRIE. 
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